FDA awards Novartis expanded approval for breast cancer therapy
Posted:
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But, the Food and Drug Administration approved Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers.
Wearable technology that monitors our bodies can be helpful and harmful.
Wearable technology affords the opportunity to check, re-check, and check again, leading to fixation.
Read the full article in the Psychology Today blog post here.
Endometriosis care has long been deprioritised and underfunded - it's time the new Labour Government changed that and offered long-awaited hope for those with endometriosis
Read more in Endometriosis UK article as part of the 'Innovations in Pain Management' campaign…
Attendees
Sponsors and
Exhibitors
Agenda
Webinars
Contact us